Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Prime Medicine (NASDAQ:PRME) stock rose 32%, extending recent gains following Eli Lilly’s (NYSE:LLY) acquisition deal for Verve Therapeutics (NASDAQ:VERV) last month.

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Prime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds. Click here to find out why ...

Gilead Sciences, a heavyweight in the biotech sector, continues to demonstrate strong relative strength trading just 5% below its 52-week high, compared with 16% for the SPDR Biotech ETF. The stock ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.

But since Tuesday, when Donald Trump said in a cabinet meeting that imported pharmaceuticals would face a massive levy, ...

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" ...

Wave Life Sciences Ltd. shows promise with AATD, DMD, and Huntington's programs. Click for my updated look at WVE stock and ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

See the latest Eli Lilly and Co stock price (LLY:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

Eli Lilly (NYSE: LLY) led the way in pharma M&A during June. The US pharma major announced two major deals in the month, both ...